Phase 3 Stomach Cancer Trial, Recruiting NCT05871099 Sponsor: The Affiliated Hospital of Qingdao University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT05871099
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have not previously received chemotherapy, radiation therapy, or any other anti-cancer treatment
  • People aged between 18 and 80 years old
  • Men, or women who are not pregnant or breastfeeding
  • People who have been confirmed by tissue testing to have stomach adenocarcinoma (a specific type of stomach cancer) and for whom keyhole (laparoscopic or robotic) surgery to remove the stomach cancer is planned
  • People whose cancer has grown to a certain depth in the stomach wall (T3 stage or deeper) with no spread to distant parts of the body, and whose cancer meets the surgical requirements for a specific type of keyhole surgery called laparoscopic D2 radical resection
  • People whose expected survival is more than 6 months
  • People who have had previous surgery outside the abdomen, or who have had keyhole gallbladder removal surgery (confirm with trial site for exact interpretation)
  • People whose blood test results show healthy bone marrow function, with white blood cell count, neutrophil count, platelet count, and haemoglobin all within acceptable ranges
  • People whose liver and kidney function blood tests fall within acceptable limits
  • People with a good general physical activity level, rated 0–1 on the ECOG performance scale (a medical scoring system for daily functioning)
  • People rated as ASA Grade I–III before surgery (a standard medical rating of overall health before an operation)
  • People who are willing to sign an informed consent form

Who may not be able to join:

  • People whose CT or MRI scan shows significantly enlarged lymph nodes — specifically, at least one lymph node measuring 3 cm or more, or three neighbouring lymph nodes each measuring 1.5 cm or more
  • Women who are pregnant or breastfeeding
  • People who have had another type of cancer within the past 5 years
  • People who have a temperature of 38°C or higher before the operation, or who have an active infection requiring treatment
  • People with a serious mental health condition
  • People with severe lung disease, where breathing test results show lung function below 50% of expected
  • People with severe liver or kidney problems, including liver enzyme levels more than twice the normal limit
  • People who have had unstable chest pain (angina) or a heart attack within the past 6 months
  • People who have had a stroke or brain bleed within the past 6 months (not including old, previously healed strokes — confirm with trial site)
  • People who have taken steroid medications (glucocorticoids) throughout their whole body within the past month
  • People whose stomach cancer has caused an emergency complication such as bleeding, a hole in the stomach wall, or a blockage requiring urgent surgery
  • People who have participated in another clinical trial within the past 6 months or are currently in one
  • People in whom internal spread of cancer within the abdomen has been confirmed through keyhole examination, tissue sampling, or fluid testing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yanbing Zhou, MD, The Affiliated Hospital of Qingdao University

Phone: 86532-82911324

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
The Affiliated Hospital of Qingdao University
Registry
ClinicalTrials.gov
Start date
20 November 2022
Est. completion
1 December 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

5-years Recurrence-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov